Vaccines against Chronic and Persistent Bacterial Infections

Collection Editor:

Prof. Dr. Alfredo G. Torres
Department of Microbiology & Immunology and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA
altorres@utmb.edu

Message from the Collection Editor

Dear Colleagues,

An important group of bacterial pathogens have developed the ability to persist and to establish life-long chronic infections in the human host. Since bacteria seems to quickly adapt to their environment and to increase survival by hijacking essential immunoregulatory mechanisms designed to reduce the pathologic process of the disease, the effort to prevent these type of infections by the use of specific vaccines seems to be a daunting task. However, newly discovered pathways used by persistent bacteria to evade the host immune system and survive within the different cells that supposed to destroy them has open up the door to the development of vaccines that can target chronic bacterial infections. Therefore, this collection is intended to highlight recent effort to develop and test promising therapeutic and/or prophylactic vaccine platforms against a diverse group of bacterial pathogens, including but not restricted to: Mycobacterium tuberculosis, Salmonella enterica, Burkholderia, Pseudomonas, Neisseria and N. meningitides, Borrellia, Brucella species, Chlamydia species and Helicobacter pylori.

Prof. Dr. Alfredo G. Torres
Collection Editor

mdpi.com/si/10324
Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Indexed in the Science Citation Index Expanded (SCIE) and BIOSIS Previews in Web of Science and in Scopus. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.43, which equals rank 12/272 (Q1) in the category 'Infectious Diseases', rank 31/198 (Q1) in 'Immunology' and rank 15/300 (Q1) in 'Pharmacology', among others.

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
vaccines@mdpi.com